Wu L, Kong XX, Zheng YP. Alprostadil combined with peritoneal lavage therapy for treatment of hyperlipidemic severe acute pancreatitis.
Shijie Huaren Xiaohua Zazhi 2015;
23:3624-3628. [DOI:
10.11569/wcjd.v23.i22.3624]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the clinical effects of alprostadil combined with peritoneal lavage therapy in the treatment of hyperlipidemic severe acute pancreatitis (HSAP).
METHODS: Twenty-seven patients with HSAP were randomly divided into two groups: a control group (13 patients) and a treatment group (14 patients). Both groups received the same conventional medical therapy, and the treatment group additionally received alprostadil and peritoneal lavage therapy (14 d as a cycle). Curative effects were compared between the two groups.
RESULTS: Compared with the control group, the time to patient's condition improvement (5.55 d ± 3.12 d vs 8.18 d ± 4.09 d, 4.14 d ± 2.94 d vs 6.75 d ± 3.58 d), the time to improvement of triacylglycerol (5.42 d ± 2.06 d vs 8.28 d ± 3.55 d), total response rate (85.71% vs 61.54%), rates of complications (21.6% vs 38.5%) and mortality (7.14% vs 15.38%), average hospital stay (23.84 d ± 7.54 d vs 31.98 d ± 12.18 d), and total expenses of the medical treatment (34.56 ± 13.44 vs 41.29 ± 18.81) were significantly better in the treatment group (P < 0.05 or P < 0.01).
CONCLUSION: Alprostadil combined with peritoneal lavage therapy is a safe and effective therapy for HSAP. It may become a basic choice for treating HSAP.
Collapse